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Objective: Limited availability of donor organs has led to the progressive expansion
of the criteria for donor selection, particularly a higher age limit of potential donors.
We retrospectively reviewed the outcomes of patients who underwent heart trans-
plantation using cardiac allografts 50 years of age and older and compared them
with patients who had donor organs younger than 50 years.
Method: Between September 1989 and May 2000, 20 patients underwent orthotopic
heart transplantation using donor hearts 50 years of age and older (range 50-56
years, mean 52.7 ± 1.8 years) and were compared with 267 patients who received
donor organs less than 50 years of age (range 9-49.9 years, mean 27.2 ± 8.6 years).
Patient and donor criteria were identical in both groups. Follow-up was 4 to 128
months with a mean of 37.4 ± 2.8 months in the older donor group and 52.6 ± 2.4
months in the younger donor group.
Results: There were no differences between these 2 cohorts of patients regarding
age, sex, cardiomyopathy, preoperative cytomegalovirus status, New York Heart
Association class, and transplant status at transplantation. Donor characteristics,
including sex, left ventricular ejection fraction, diabetes, cytomegalovirus status,
and allograft ischemic times, were also similar in the 2 groups. Donor/recipient
cytomegalovirus matching showed no differences as well. Thirty-day or to dis-
charge operative mortality was similar in the older and younger donor groups (5%
± 4.8% vs 3.5% ± 1.1%; P = .84). Actuarial survival at 1 and 5 years was also sim-
ilar in both groups (89.7% ± 6.9% vs 91% ± 1.8% and 53.1% ± 14.7% vs 71.0% ±
3.1%, respectively; P = .59). No patient in the older donor group required coronary
artery bypass grafting or retransplantation during the follow-up period, whereas 2
patients in the younger donor group required coronary artery bypass, and 5 patients
underwent retransplantation (P ≥ .50). Two patients in the older donor group died
of nonspecific allograft failure, whereas 3 patients in the younger donor group expe-
rienced similar posttransplant complication (P ≥ .50).
Conclusions: Carefully selected donor hearts 50 years of age and older can be used
for heart transplantation with long-term survival and related outcomes similar to
those of younger donor organs. This use of selective cardiac allografts maximizes
donor organ usage and expands the donor pool effectively without an adverse
impact on long-term results.
As the effectiveness of heart transplantation for the treatment ofend-stage heart disease has long been proven, the pressure to meetthe increasing demand for donor organs has led the transplantcommunity to broaden and expand the criteria for donor accep-tance. The use of high-risk cardiac allografts has been advocatedto expand the donor pool and to meet the supply-demand mis-
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match for patients awaiting heart transplantation. Although
there is evidence from the Registry of the International
Society of Heart and Lung Transplantation (ISHLT) that
older donors have an adverse prognosis,1 other reports indi-
cate that advanced donor age is not necessarily associated
with poor results and would seem a viable option for
selected patients.2-6 To assess the effect of increased donor
age on final outcome, we retrospectively analyzed the
results of 20 patients who underwent heart transplantation
using cardiac allografts 50 years of age and older over an
11-year period. We then compared these results with those
of 267 patients who received donor organs less than 50
years of age over the same period, using identical immuno-
suppression and cytomegalovirus (CMV) prophylaxis pro-
tocols.
Patients and Methods
Between September 1989 and May 2000, 287 patients underwent
heart transplantation at Cedars-Sinai Medical Center. Of those, 20
patients received donor organs 50 years of age and older (range
50-56 years, mean 52.7 ± 1.8 years), whereas the remaining 267
patients received cardiac allografts younger than 50 years of age
(range 9-49.9 years, mean 27.2 ± 8.6 years). Cardiac allografts 50
years of age and older were allocated preferentially to recipients
50 years of age and older unless there was a younger patient with
an urgent need for a donor heart. The United Network for Organ
Sharing (UNOS) and the specific organ procurement agency
established the guidelines for donor organ allocation (eg, priority
status and time accrued in the waiting list, taking into considera-
tion the recipient’s blood type, weight, sex, pulmonary vascular
resistance, and transpulmonary gradient, among others). The mean
age of those status 1 transplant patients with donor organs 50 years
of age and older was 58.3 ± 11.0 years (range 41-69 years),
whereas it was 64.0 ± 9.7 years (range 42-74 years) for those
patients waiting as status 2. The preoperative patient characteris-
tics are shown in Table 1. Since all recipients were listed for trans-
plantation by the same selection criteria, the potential differences
in the myocardial oxygen consumption values, pulmonary artery
pressures, pulmonary vascular resistance, transpulmonary gradi-
ents, or the number of previous cardiac operations between the
older and the younger donor patient groups were thought to be
nonsignificant and, thus, not analyzed separately. Donor heart and
intraoperative characteristics are presented in Table 2. Our criteria
to evaluate potential donors were identical in both groups, and a
TABLE 1. Preoperative recipient characteristics
Donor ≥ 50 Donor < 50
years (n = 20) years (n = 267) P value
Age at transplant (y)
Mean ± SD 67.1 ± 10.4 56.4 ± 11.1 <.05
Range 41-74 14-77
Sex
Male 16 (80%) 228 (85%) .52
Female 4 (20%) 39 (15%)
Cardiomyopathy
Ischemic 13 (65%) 157 (59%) .16
Idiopathic 6 (30%) 103 (38.4%)
Congenital 1 (5%) — (0%)
Chagas disease — (0%) 3 (1%)
Other — (0%) 4 (1.6%)
CMV status
Positive 17 (85%) 190 (71%) .14
Negative 3 (15%) 77 (29%)
NYHA class
II — (0%) 17 (6%) .23
III 10 (50%) 17 (32%)
Transplant status (UNOS)
1 8 (40%) 170 (64%) .05
2 12 (60%) 97 (36%)
Waiting time to
transplantation (mo)
Mean ± SD 2.8 ± 1.4 3.8 ± 1.9 <.05
Range 1-9 1-37
CMV, Cytomegalovirus; NYHA, New York Heart Association; UNOS, United
Network for Organ Sharing; SD, standard deviation. 
TABLE 2. Donor heart and intraoperative characteristics
Donor ≥ 50 Donor < 50
years (n = 20) years (n = 267) P value
Age (y)
Mean ± SD 52.7 ± 1.8 27.2 ± 8.6 <.05
Range 50-56 9-49.9
Sex
Male 16 (80%) 194 (73%) .61
Female 4 (20%) 73 (27%)
LVEF
≥50% 18 (90%) 247 (93%) .66
40–50% 2 (10%) 20 (7%)
Diabetes mellitus 1 (5%) 2 (1%)
Pretransplant angiogram n = 13 n = 16 N/A
Abnormal angiogram (CAD) 4 (31%) 2 (13%)
Allograft ischemic time (min)
Mean ± SD 163 ± 36.8 161 ± 17.0 .50
Range 65-250 60-327
Associated surgery (CABG) 1 (5%) 2 (0.7%)
Allograft CMV status 
Positive 11 (55%) 167 (62%) .63
Negative 9 (45%) 100 (38%)
Donor/recipient CMV
matching
D+/R+ 9 (45%) 116 (43%) .62
D+/R– 2 (10%) 51 (19%)
D–/R+ 8 (40%) 74 (28%)
D–/R– 1 (5%) 26 (10%)
LVEF, Left ventricular ejection fraction; CAD, coronary artery disease;
CABG, coronary artery bypass grafting; CMV, cytomegalovirus; SD, stan-
dard deviation.
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preoperative coronary angiogram was requested for donors 40
years of age and older or for donor hearts with segmental wall
motion abnormalities seen on echocardiography. However, a pre-
operative coronary angiogram or echocardiogram was not always
available at the donor hospital. Thus, in the absence of these tests,
the decision was made by the harvesting surgeon on the basis of
visual inspection and examination of the donor heart. Those
patients who received a cardiac allograft older than 40 years of age
without a preoperative coronary angiogram or echocardiogram
underwent these studies before discharge from the hospital.
Follow-up was 4 to 128 months with a mean of 37.4 ± 2.8 months
in the older donor group and 52.6 ± 2.4 months in the younger
donor group.
For the statistical analysis, continuous variables were analyzed
with the use of a 2-sample t test to compare differences between
the 2 donor groups. Categorical variables were analyzed by the
Fisher exact test.
Immunosuppressive Therapy
Immunosuppressive therapy consisted of OKT3 induction therapy
(5 mg intravenously daily) for 7 days. However, patients with
impaired renal function (serum creatinine > 2.5 mg/dL) or patients
undergoing combined heart-kidney transplantation received
antithymocyte globulin (ATG) (15 mg/kg daily, adjusted for white
blood cell count and platelet count) for 7 days. Maintenance
immunosuppressive therapy consisted of cyclosporine (INN:
ciclosporin) (5 mg/kg per day, for a level of 200 to 400 ng/mL, as
measured by a monoclonal fluorescence polarization immunoas-
say, within the first 12 weeks after transplantation, and a level of
120 to 200 ng/mL thereafter, started postoperatively once the
serum creatinine was less than 2.0 mg/dL); azathioprine (4 mg/kg
preoperatively, and 2 mg/kg per day postoperatively, adjusted to
the patient’s white blood cell count and platelet count), but
switched to mycophenolate mofetil (1000 mg twice daily) for all
patients as of January 1997 (includes 7 patients in the older donor
group and 73 patients in the younger donor group); and steroids
(methylprednisolone sodium succinate, 1 mg at removal of the
aortic crossclamp intraoperatively, and then 125 mg intravenously
every 8 hours for 3 doses postoperatively, followed by prednisone,
0.25 mg/kg per day during OKT3 or ATG therapy, increased to 0.5
mg/kg per day, and then tapered off in the subsequent 3 to 8
months). Endomyocardial biopsies were performed according to
our surveillance protocol or when acute cardiac rejection was clin-
ically suspected. Cardiac rejection episodes were treated if greater
than 1 B (International Society for Heart and Lung Transplantation
classification). Routine 2-dimensional echocardiograms and coro-
nary angiograms were performed at yearly intervals or more fre-
quently when clinically indicated. 
Cytomegalovirus Prophylaxis
Most patients were given 6 doses of intravenous immunoglobulin
(500 mg/kg) within 1 week after transplantation, with 5 doses of
intravenous cytomegalovirus (CMV) specific immune globulin
(125 mg/kg) after the first intravenous immunoglobulin dose.
Intravenous ganciclovir was also administered (5 mg/kg every 12
hours but adjusted for renal function) for 14 weeks followed by
oral ganciclovir (1000 mg twice daily but adjusted for renal func-
tion) for an additional 38 weeks for those patients who were donor
CMV positive/recipient CMV negative (high risk). For those
patients donor CMV positive/recipient CMV positive and for
those donor CMV negative/recipient CMV positive (low risk),
prophylaxis consisted of 6 doses of intravenous immunoglobulin
and intravenous ganciclovir for 2 weeks followed by oral acyclovir
(3200 mg daily but adjusted for renal function) for 24 weeks.
Prophylaxis for high-risk patients spanned the first posttransplan-
tation year, whereas CMV prophylaxis for low-risk patients lasted
the first 6 months after transplantation. 
Results
The 30-day or to discharge operative mortality was similar
in the older and the younger donor groups (5% ± 4.8% vs
Figure 1. Thirty-day operative survival and actuarial survival up to 5 years for both donor age groups. ns, Not signifi-
cant; SE, standard error.
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3.5% ± 1.1%, P = .84). Actuarial survival at 1 and 5 years
also was similar in both groups (89.7% ± 6.9% vs 91% ±
1.8% and 53.1% ± 14.7% vs 71.0% ± 3.1%, respectively, P
= .59) (Figure 1). One patient in the older donor group and
2 patients in the younger donor group required concomitant
coronary artery bypass grafting (CABG) at the time of
transplantation and are alive and well at 24, 12, and 75
months, respectively. The incidences of posttransplant
CMV infection and allograft rejection (>1 B) were also sim-
ilar and are shown in Table 3. Insufficient data preclude
comparison of posttransplant incidence of percutaneous
transluminal coronary angioplasty/stent interventions in
both groups. No patients in the older donor group required
CABG for significant allograft coronary artery disease
(CAD) or retransplantation for allograft vasculopathy or
nonspecific graft dysfunction during the follow-up period.
Two patients in the younger donor group required CABG
(at 25 and 36 months, respectively), and an additional 5
patients required retransplantation (at 1, 19, 43, 48, and 73
months, respectively) (P ≥ .50). The mean posttransplant
left ventricular ejection fraction in the older donor group
was 56.5% ± 13.4% (range 45%-72%), but a statistically
significant comparison with the younger donor group could
not be made because of insufficient data in the latter group.
Two patients in the older donor group died of nonspecific
allograft failure in the late follow-up period (at 18 and 27
months, respectively), whereas 3 patients in the younger
donor group had similar posttransplant complication (at 13,
21, and 42 months, respectively) (P ≥ .50). Their post-
mortem diagnosis was confirmed in all patients by autopsy.
The causes of death are shown in Table 4.
Discussion
The use of donor hearts from high-risk donors has allowed
for the expansion of the donor pool and increased organ
recovery rates of 20% to 30% annually.7 However, the use of
these high-risk cardiac allografts should be very selective,
and the potential benefits should far outweigh the risks. This
is particularly true for older donors, although there is no con-
sensus on what constitutes an older donor. Donor age has
traditionally been considered a risk factor for the develop-
ment of CAD in the transplanted allograft with subsequent
increased morbidity and mortality and allograft vasculopa-
thy.1,8-10 Further, an analysis of the UNOS database showed
that older donors have a significant increase in early postop-
erative mortality and 1-year mortality that persists at the 5-
year point. Advanced donor age is known to be a strong
adverse predictor of mortality second only to retransplanta-
tion.11 In addition, there is a statistically significant interac-
tion between allograft ischemic time and donor age that
affects short- and long-term survival.1 In a study by Loebe
and colleagues,2 the incidence of posttransplant cardiac
events was much lower when younger donors were used. It
included a lower rate of percutaneous transluminal coronary
angioplasty, CABG, and retransplantation with donor hearts
less than 35 years of age compared with donor hearts 35 to
50 years and those older than 50 years of age.2
However, some of these unfavorable results may be due
to the fact that older donor hearts traditionally have been
allocated to older recipients or high-risk patients and even
used as a “biologic bridge” to transplantation until a
younger allograft could be available.2,6,12 Data from the
Registry of the ISHLT1 show that advanced recipient age is
another strong factor that adversely affects survival, which
may further compound the increased mortality associated
with older donors. With the ever-expanding heart transplant
recipient population, new strategies for increasing the donor
pool have been pursued and the lack of the “ideal” donor
heart has expanded the criteria for acceptance of potential
donors. Older donor hearts with negative cardiac history
and serologies, normal electrocardiogram and echocardio-
gram, low inotropic support, normal coronary angiogram,
and an expected short ischemic time may fill this void. In a
study by Ibrahim and colleagues,5 extended ischemic time
(>240 minutes, mean 255.8 ± 6.9 minutes) and increased
donor age (>40 years, mean 46.4 ± 0.8 years) did not
adversely affect early survival after heart transplantation
although no long-term survival was reported. Although
some series have reported satisfactory intermediate and
TABLE 3. Postoperative CMV infection and allograft
rejection
Donor ≥ 50 y Donor < 50 y P value
CMV infection 2 (10%) 12 (4.5%) .26
Rejection ≥1B* 4 (20%) 106 (40%) .09
CMV, Cytomegalovirus.
*International Society for Heart and Lung Transplantation classification.
TABLE 4. Cause of death
Donor ≥ 50 y Donor < 50 y
(n = 7) (n = 71)
Allograft atherosclerosis 2 23
Nonspecific graft failure 2 3
Sepsis 1 11
Cancer — 17
Renal failure — 4
Acute right ventricular failure — 2
Mediastinal hemorrhage — 2
Acute rejection 1 1
Sudden death 1 —
Other — 8
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long-term results after heart transplantation with the use of
older donors,2,3,6,8,12-14 there are studies that suggest that
the extension of the donor age predisposes the recipient to
allograft vasculopathy.2,8
The role of CMV infection has been postulated to accel-
erate the development of allograft vasculopathy in older car-
diac allografts although the exact mechanism is not clearly
known.15 As older individuals, and thus potential donors,
tend to have a higher percentage of CMV seropositivity, this
may adversely affect the development of CMV disease in
recipients with older allografts.16 Our experience as well as
others2 indicates no significant difference in the incidence of
postoperative CMV infection or allograft rejection.
Some investigators advocate the use of selective, rather
than routine, coronary angiography to evaluate the presence
of CAD in the older donor heart.2,4 As invasive preoperative
studies are not always available at the donor hospital, these
potential cardiac allografts should be carefully examined by
visual inspection and palpation of the coronary arteries,
although the sensitivity and specificity of such techniques
are limited. In our experience, coronary arteriography was
available in 65% of our older donor population. In the
remaining 7 patients, this study was performed before dis-
charge and failed to show any significantly obstructive
coronary artery lesion in all of them. Although it appears
that there is an increased incidence of CAD requiring post-
transplant CABG and retransplantation in the younger-age
donor group, along with a longer mean follow-up time, it
did not achieve statistical significance. Only long-term fol-
low-up of these 2 groups of heart transplant recipients
involving large numbers of patients will accurately deter-
mine the true incidence of significant CAD in each cohort
of patients. Thus, it may influence the use of older donors
for heart transplantation. However, Chau and colleagues6
reported a much greater incidence of chronotropic incom-
petence requiring placement of a permanent pacemaker in
patients with older donor hearts that was independent of
allograft ischemic time and pretransplantation amiodarone
therapy. This seems to be a technical rather than a physio-
logic or an age-related event. We have completely abolished
the need for a permanent pacemaker because of sinus node
dysfunction in the early posttransplant period in our last 236
consecutive patients undergoing heart transplantation. This
was accomplished by adopting an alternative technique for
implantation of the cardiac allograft consisting of bicaval
and pulmonary venous anastomoses as our standard tech-
nique, including all the patients reported in this study.17
Further, even though there was a slight modification in the
immunosuppressive protocol for all patients in the last 3
years of this study, it had no direct impact on the survivals
in either group.
Although there are some limitations and methodologic
restrictions of this study—such as the small number of
patients involved in the older donor group and the insuffi-
cient data regarding posttransplant angioplasty/stent inter-
ventions (usually performed at the referring
hospital)—some valid conclusions can be drawn. On the
basis of our experience with older donor hearts, we believe
that donor age per se should not be a contraindication for
consideration for heart transplantation. These older donor
hearts should be accepted regardless of age, provided they
demonstrate satisfactory physiologic and hemodynamic
performance. In fact, our allocation criteria for cardiac allo-
grafts 50 years of age and older have evolved since the com-
pletion of this study; those donor organs are now matched
with the proper recipient on the basis of the clinical charac-
teristics of the donor and recipient, regardless of the recipi-
ent’s age. Exception is made in those rare circumstances of
donor organs with documented limited CAD that require
concomitant CABG at the time of allograft implantation;
those cardiac allografts are usually matched with recipients
60 years of age and older who are in urgent need of trans-
plantation. The selective use of older allografts for heart
transplantation maximizes organ use and would expand the
donor pool without an adverse effect on long-term results.
This approach implies a careful selection and close surveil-
lance for the development of allograft vasculopathy.
Further, even the use of the “less than ideal” older donor
heart should be considered and assessed on a case-by-case
basis. Such is the case when mild to moderate CAD is pres-
ent or a more prolonged period of allograft ischemic time
would be expected, provided it is selectively allocated to the
proper recipient. An exception to these expanded criteria is
the use of hepatitis C-positive donors, even in hepatitis C-
positive recipients since there is more than one strain of the
virus and the presence of antiviral antibody does not guar-
antee immediate immunity.18 Experience with kidney trans-
plantation19 indicates that nearly all recipients from
hepatitis C–positive donors become infected with the virus.
There is no reason to believe that hepatitis C–positive or
hepatitis B–positive cardiac allografts would behave any
differently.
Finally, with the exponential expansion of heart trans-
plant recipient lists and the limited donor organ availability,
the use of the less than ideal cardiac allograft has become a
necessity and is no longer an isolated event. There is an
accepted attitude to “bend the rules” and expand these cri-
teria for the urgent transplant recipient with otherwise no
possibility for survival. An older donor heart has tradition-
ally represented a high-risk donor, but the clinical and ethi-
cal dilemma has been partially answered by the satisfactory
long-term results achieved with the use of other “unaccept-
able” heart donors in younger and not so critically ill
patients.12 The objective of applying selection criteria to
organ donors is to provide recipients with the optimum
chance for a successful transplantation, and our study may
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help clarify this issue. When faced with a critically ill
patient awaiting transplantation, we believe an available
donor heart represents a viable alternative to mechanical
assist devices (with their attendant inherent morbidity and
mortality). Does an older cardiac allograft (defined as 50
years of age and older), with normal anatomic and physio-
logic function, represent a higher risk alternative then a
mechanical ventricular assist device? Although the compar-
ison of survivals of such alternatives is not clearly known,
the reluctance of many transplant centers to use older donor
organs for heart transplantation must be balanced against
the disparity that exists between supply and demand of
donor organs. Unfortunately, this gap continues to grow and
such devices will not alleviate the exponentially growing
demand for donor organs.
Is the use of older donor hearts for transplantation only
acceptable to older recipients, in whom the feasibility of a
mechanical assist device may be limited or perhaps con-
traindicated, or is it equally applicable to younger recipients
awaiting heart transplantation in a more elective fashion?
Many facets of this study warrant further investigation to
answer the many questions raised, but the satisfactory
results with this group of older donor hearts may expand the
acceptance criteria even further in the future. In addition, it
is fundamentally important to recognize patients’ prefer-
ences regarding the different alternatives available, particu-
larly for the younger and the not so urgent patients waiting
for transplantation, to reconcile the practical, clinical, and
moral issues involved.
A careful follow-up and continued analysis of these data
from larger series and/or multicenter studies may define the
true risks and benefits of this approach and may guide the
limits of expanding the donor criteria. 
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